News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Data From Phase II Study Of Progenics (PGNX)’ PSMA-Targeted Imaging Agent 1404 Published In Journal Of Nuclear Medicine 3/24/2017
How This New Jersey Biotech is Taking on Amgen (AMGN) 3/24/2017
Xenon Pharmaceuticals Inc. Dumps Acne Drug After Trial Failure 3/24/2017
Bay Area's Ultragenyx (RARE) Tanks as Seizure Drug Flunks Phase II Test 3/23/2017
Why Struggling Bristol-Myers Squibb (BMY) Could Take Out This Danish Biotech in Major €500M Deal 3/23/2017
5 Biotechs That Have Major Catalysts Coming in the Next 6 to 9 Months 3/23/2017
Novartis AG (NVS)'s Phase III Drug for Heart Failure Bombs Trial 3/23/2017
How This Drug Candidate Could be a Winner in Gilead (GILD)'s Pipeline 3/23/2017
Centrexion To Present Data On CNTX-4975 From The Treatment Of Knee Osteoarthritis Pain At IX SIMPAR-ISURA 3/23/2017
Confidential Data From Genervon ALS Phase IIA Clinical Trial Were Released And Published 3/23/2017
Heat Biologics (HTBX) Rockets as Lung Cancer Med Hits Mid-Stage Goals 3/22/2017
AVEO Oncology (AVEO) Announces First Patient Dosed In Phase 1/2 Tinivo Trial Of Tivozanib And Opdivo (Nivolumab) In Advanced RCC 3/22/2017
InDex Pharmaceuticals AB Concludes Well Attended Investigators' Meeting For The Phase IIb Study Conduct 3/22/2017
BeyondSpring Pharmaceuticals Chief Medical Offer To Present On Lead Asset Plinabulin For Chemotherapy-Induced Neutropenia Prevention At BIO-Europe Spring 2017 3/22/2017
Moleculin Biotech (MBRX) Receives Orphan Drug Designation For Annamycin For The Treatment Of Acute Myeloid Leukemia 3/22/2017
Poxel SAS Announces Positive Results For Thorough QT Safety Clinical Study Of Imeglimin 3/21/2017
Syntimmune Announces Breakthrough Results Of FcRn Inhibition Published In PNAS 3/21/2017
Phase II/II Clinical Trial Of Apexigen's APX005M In Combination With Pembrolizumab (Keytruda) Opens For Metastatic Melanoma Patients 3/21/2017
Dermira (DERM) Presents New Data Highlighting Patient Outcomes In Axillary Hyperhidrosis At Maui Derm Meeting 3/21/2017
NETRIS Pharma Starts Enrollment Of First Clinical Study To Evaluate Drug Candidate Targeting Dependence Receptors 3/21/2017
This Cheap Michigan Biotech Could Have Major Phase II Catalysts Coming 3/20/2017
NightstaRx Commences First Phase I/II Gene Therapy Clinical Trial For Patients With X-Linked Retinitis Pigmentosa 3/20/2017
Cytokinetics (CYTK) Announces Additional Results From COSMIC-HF Presented At American College of Cardiology.17 3/20/2017
Neothetics (NEOT) Announces Last Subject Enrolled In Phase II Proof Of Concept Trial For LIPO-202 For The Reduction Of Submental Subcutaneous Fat 3/20/2017
BioLineRx Provides Update On Phase II Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment 3/20/2017
Dynavax (DVAX) Announces Upcoming Data Presentations For Three TLR9 Agonist Programs At The 2017 AACR Annual Meeting 3/20/2017
BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment 3/20/2017
Major Achievements In 2016 Validate TRANSGENE (ENX:TNG)’s Strategy And Provide Promising Outlook For 2017 3/20/2017
NantKwest Announces FDA Grant Of Orphan Drug Designation For The Company’s aNK Natural Killer Cell Therapy In Merkel Cell Carcinoma 3/20/2017
Selvita Announces First Patient Dosed In Phase I/II Clinical Trial Of SEL24 In Acute Myeloid Leukemia 3/17/2017
Karolinska Development AB Umecrine Cognition Announces First Patient Included In Clinical Phase Ib/IIa Study With GR3027 For Hepatic Encephalopathy 3/17/2017
The Medicines Company (MDCO) And Alnylam (ALNY) Report Positive Final Results From ORION-1 Phase II Study Of Inclisiran 3/17/2017
Acceleron Pharma Announces Plans To Initiate A Phase II Trial Of ACE-083 In Charcot-Marie-Tooth Neuromuscular Disease And Host Educational Webinar 3/16/2017
Centrexion To Present Late-Breaking Poster At The 33rd Annual American Academy Of Pain Medicine Meeting 3/16/2017
Seres Therapeutics (MCRB) to Launch New SER-109 Clinical Study to Treat Hospital Infections 3/16/2017
Vtesse Completes Enrollment Of Phase IIb/III Pivotal Clinical Trial Of VTS-270 In Niemann-Pick Type C1 Disease 3/15/2017
Immunomedics (IMMU) Announces Publication Of Results In Journal Of Clinical Oncology, Demonstrating Treatment With Sacituzumab Govitecan (IMMU-132) Produces Early And Durable Responses In Patients With Metastatic Triple-Negative Breast Cancer 3/15/2017
Advaxis (ADXS) Presents Oral Late-Breaking Data On Phase II GOG-0265 Study Of Axalimogene Filolisbac At SGO’s Annual Meeting On Women’s Cancer 3/15/2017
Catalyst Pharma (CPRX) Neuromuscular Drug Hits Goals In Study 3/15/2017
The Medicines Company (MDCO) To Webcast Presentation Of ORION-1 Phase II Study Of Inclisiran At American College of Cardiology 17 3/14/2017
TapImmune (TPIV) Announces Fully Funded Phase II Clinical Study Of HER2-Targeted Vaccine In Early Breast Cancer 3/14/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders 3/14/2017
MetrioPharm AG Announces Positive Top-Line Results From A Phase IIa Study In Moderate-To-Severe Psoriasis With Its Oral Lead Compound MP1032 3/14/2017
Sanofi (SNY) And Voluntis Announce A Global Alliance To Deliver Digital Insulin Titration Solutions For People With Type II Diabetes 3/14/2017
Clovis Oncology (CLVS) Presents New Data From Phase II Studies Of Rucaparib In Advanced Ovarian Cancer At 2017 SGO Annual Meeting On Women’s Cancer 3/13/2017
Kiadis Pharma To Present Atir10 Phase II Trial Data In Late Breaking Abstract At The International Society For Cellular Therapy (ISCT) 2017 Annual Meeting 3/13/2017
TiGenix Announces Top-Line Phase I/II Results Of AlloCSC-01 In Acute Myocardial Infarction 3/13/2017
Selvita To Present New Data From Its Oncology Programs At The Upcoming AACR Annual Meeting 2017 3/13/2017
Zynerba (ZYNE) Announces Completion Of Enrollment For ZYN002 In Two Phase II Clinical Trials For Epilepsy And Osteoarthritis 3/13/2017
Heat Biologics Meets Efficacy Endpoint In Its Phase Ib Lung Cancer Trial To Progress To Phase II 3/13/2017
BioPharmX Society Of Toxicology Poster Suggests Promise Of BPX-01 As Topical Acne Therapy, Highlights Safety 3/13/2017
First Patient Dosed In Phase 2 Trial Evaluating TRANSGENE (ENX:TNG)’s TG4010 In Combination With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 3/13/2017
Nature Cell Started Commercial Clinical Trials Phase I And II "ASTROSTEM," Stem Cell Drug For Alzheimer's Disease Treatment In U.S. 3/10/2017
REGiMMUNE Phase IIa Results Of RGI-2001, An Activator Of Invariant Natural Killer T Cells, Published In "Biology Of Blood And Marrow Transplantation" 3/10/2017
Galapagos (GLPG.BR) Release: New Phase II Studies With Filgotinib In Small Bowel And Fistulizing Crohn's Disease 3/10/2017
Tyrogenex Completes Patient Enrollment In Its Phase II Trial Of Orally Administered Vorolanib For Wet Age-Related Macular Degeneration 3/9/2017
Bone Therapeutics Completes Recruitment Of 16 Patients In ALLOB Phase I/IIA Delayed-Union Study 3/9/2017
Ironwood (IRWD) Showcases Progress Delivering Innovative Medicines To Patients And Building A Top-Performing Commercial Biotech At R&D Day 2017 3/9/2017
Boehringer Ingelheim Grants Orphan Drug Designation To Boehringer Ingelheim's Investigational Anti-CD33 Monoclonal Antibody BI 836858 For Treatment Of Myelodysplastic Syndromes 3/9/2017
eFFECTOR' Lead Product Candidate, Eft508, Receives Orphan Designation From FDA For Treatment Of Diffuse Large B-Cell Lymphoma 3/9/2017
ProtoKinetix Inc. (PKTX.OB) Announces Start Of Phase I & Phase II Clinical Trials For The Use Of AAGP PKX-001 Treated Islet Cells In The Treatment Of Type 1 Diabetes 3/9/2017
Ipsen (IPN.PA) Announces Data Presentations Of Lanreotide (Somatuline Autogel), Telotristat Ethyl And The Investigational Compound 177Lu-OPS201 At The European Neuroendocrine Tumor Society (ENETS) 2017 Conference 3/9/2017
Why Ionis Pharma (IONS)'s Extensive And Deep Pipeline Could Get Investors' Hearts Pumping 3/8/2017
NuvOx Pharma And University of Arkansas Initiate Phase Ib/II Clinical Trial In Stroke 3/8/2017
Corbus (CRBP) To Present Gene Expression Data From Recent Phase II Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation And Fibrosis Pathways 3/8/2017
Catalyst Biosciences Reports Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update 3/8/2017
Menlo Therapeutics Announces Successful Pruritus Reduction Results From Phase 2 Serlopitant Trial (TCP-102) In 127 Subjects With Prurigo Nodularis 3/8/2017
Neurim Pharmaceuticals Release: Phase II Clinical Trial For Treatment Of Mild Alzheimer's Disease 3/7/2017
Innovative Med Concepts Release: Journal Of Pain Research Publishes Results Of PRID-201, A Successful Phase II Trial Using IMC-1 For The Treatment Of Fibromyalgia 3/7/2017
Knopp Biosciences Announces Publication Of Eosinophil-Lowering Effects Of Dexpramipexole In Multiple Clinical Trials 3/7/2017
Aurinia (AUPH) Announces Acceptance Of Voclosporin Late-Breaking Presentation At National Kidney Foundation 2017 Spring Clinical Meetings 3/7/2017
Shire (SHPG) Release: CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy 3/7/2017
Axim Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome With Canchew Plus® Cannabidiol (CBD) Chewing Gum 3/7/2017
Cytokinetics (CYTK) Announces Presentation Of Additional Results From COSMIC-HF At American College of Cardiology17 3/7/2017
Innate Immunotherapeutics Release: Multiple Abstracts Concerning MIS416 Mechanism Of Action Accepted For Presentation At Upcoming American Academy Of Neurologists Meeting 3/7/2017
Aurinia (AUPH) Announces Acceptance Of Voclosporin Late-Breaking Presentation At National Kidney Foundation 2017 Spring Clinical Meetings 3/7/2017
Esperion (ESPR) Announces Initiation Of Phase II Triplet Oral Therapy Study Of Bempedoic Acid/Ezetimibe/Atorvastatin 3/7/2017
GlycoMimetics, Inc. (GLYC) Completes Enrollment Of Newly Diagnosed AML Patient Cohort In Phase II Clinical Trial Of GMI-1271 3/7/2017
Viamet Presents Positive Results From Phase IIb Trial Of VT-1161 In Onychomycosis At American Academy of Dermatology Annual Meeting 3/6/2017
Castle Creek Pharma Announces Presentation Of Phase II Clinical Data For Diacerein 1% Ointment In Treatment Of Epidermolysis Bullosa Simplex 3/6/2017
Samumed Presented Data On Increases In Hair Follicles Observed In Its Phase II Biopsy Study For A Potential Treatment Of Androgenetic Alopecia (AGA) At Annual Meeting Of American Academy of Dermatology 3/6/2017
NuvOx Pharma And The University of Arkansas Initiate Phase Ib/II Clinical Trial In Stroke 3/6/2017
Mast Therapeutics (MSTX) Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients 3/6/2017
An Expected Failure From Karyopharm (KPTI)'s Selinexor Doesn't Change The Bull Thesis 3/6/2017
Abzena Inside Product For Neurodegenerative Conditions Moves Into Phase II Trial 3/6/2017
Galectin (GALT)’s GR-MD-02 Demonstrates Efficacy In Patients With Moderate To Severe Plaque Psoriasis 3/6/2017
Dynavax (DVAX) Presents Promising Clinical Data From Lead Immuno-Oncology Candidate, SD-101, At The International Congress On Targeted Anticancer Therapies 3/6/2017
Matinas BioPharma And NIH/NIAID Initiate Open-Label Extension To Phase IIa Study Of MAT2203 In Chronic Mucocutaneous Candidiasis 3/6/2017
Kura Oncology Reports Updated Clinical Activity Data In Ongoing Phase II Trial For Tipifarnib 3/6/2017
Revance (RVNC) Announces BELMONT Phase II Clinical Data To Be Presented At The 2017 American Academy of Dermatology (AAD) Annual Meeting 3/3/2017
Kamada Ltd. (KMDA) To Host R&D Day Focused On Graft Versus Host Disease (GvHD) 3/3/2017
LEO Pharma Announces Positive Results From Phase 2b Clinical Study For Tralokinumab In Atopic Dermatitis 3/3/2017
FDA Grants Orphan Drug Designation To ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Drug For The Treatment Of Alström Syndrome 3/3/2017
Novartis AG (NVS) Puts Cancer Hopes on 4 Star Scientists Poached From Harvard Last Year 3/3/2017
Kite Pharma (KITE)'s CAR-T Blood Cancer Candidate Succeeds in Major Study 3/2/2017
Chugai Pharma's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "Nemolizumab (CIM331)" Global Phase II Study Data Published In The New England Journal of Medicine Online 3/2/2017
bluebird bio (BLUE) Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal of Medicine 3/2/2017
Sangamo Therapeutics (SGMO) Receives Orphan Drug Designation From The FDA For SB-913 Genome Editing Treatment For MPS II 3/1/2017
Adynxx Initiates ADYX-004, A Phase II Study Of AYX1, Lead Compound For The Treatment Of Post-Surgical Pain 3/1/2017
Audentes (BOLD) Announces Commencement Of LUSTRO, A Clinical Assessment And Phase I/II Run-In Study Of Patients With Crigler-Najjar Syndrome 3/1/2017
SELLAS Life Sci Announces Updated Positive Phase II Data Reinforcing Meaningful Clinical Benefit Of Its WT1 Immunotherapeutic Anti-Cancer Treatment In Multiple Myeloma Patients 3/1/2017
Omeros (OMER) Reports Additional Positive Results From OMS721 Phase II Trial In Patients With Stem Cell Transplant-Associated Thrombotic Microangiopathy 3/1/2017
Viamet Announces RENOVATE Phase IIb Onychomycosis Results To Be Presented At American Academy of Dermatology 2017 Annual Meeting 3/1/2017
Zogenix (ZGNX) Receives Orphan Drug Designation In The European Union For ZX008 In Lennox Gastaut Syndrome 3/1/2017
NeuroDerm (NDRM) Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson’s Disease; Seeks Broader EU Label Based On Indigo Trial Following EMA Meeting 3/1/2017
Realm Therapeutics: FDA Permits PR022 To Proceed To Phase 2 Trial 3/1/2017
Neurotrope Concludes Patient Dosing And Monitoring In Its 148 Patient Phase II Clinical Trial Of Moderate To Severe Alzheimer's Dementia 2/28/2017
Dermira (DERM) Data From DRM04 And Olumacostat Glasaretil Clinical Programs To Be Presented At American Academy of Dermatology Annual Meeting 2/28/2017
Immune Pharma Reports Encouraging Preliminary Data With Bertilimumab In An Open Label Phase II Study In The Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid 2/28/2017
Roche (RHHBY)'s Renal Success Spells Danger For All-Comer Studies 2/27/2017
TheraVida, Inc. Announces Publication Of Phase II Results For THVD-102 In Hyperhidrosis 2/27/2017
Enrollment Completed In Ligand (LGND)’s Phase II Trial Of LGD-6972 In Type 2 Diabetes 2/27/2017
Biothera Announces Presentation Of Clinical Data Supporting Use Of A Patient Selection Biomarker For Its Phase II Cancer Immunotherapy 2/27/2017
OncoSec Medical Granted FDA Fast Track Designation For Immunopulse IL-12 For The Treatment Of Metastatic Melanoma Following Progression On Pembrolizumab Or Nivolumab 2/27/2017
Syros Pharma Reports Discovery Of Novel Genomics Based Approach To Stratifying Patients With Acute Myeloid Leukemia At Cold Spring Harbor Conference 2/27/2017
Study Of SanBio, Inc.'s Stem Cell Treatment For Stroke Receives Innovation Award From AHA 2/27/2017
Biocryst (BCRX) Reports Positive Interim Results From Its APeX-1 Trial 2/27/2017
Addex Therapeutics (ADXN.SW)'s ADX71149 Anti-Epileptic Effect Highlighted In Scientific Journal, Epilepsia 2/27/2017
Why 2017 Will be a Data-Rich and Not Revenue-Focused Year for bluebird bio (BLUE) 2/24/2017
Nivalis (NVLS) Announces Results From Phase II Clinical Trial Of Cavosonstat Added To Ivacaftor For Treatment Of Cystic Fibrosis 2/24/2017
Symic Biomedical Announces Last Patient Enrolled In SHIELD Trial Of SB-030 For Interventions In Peripheral Artery Disease 2/24/2017
Tocagen Receives Breakthrough Therapy Designation From FDA For Toca 511 & Toca FC In Recurrent High Grade Glioma 2/23/2017
Reata Pharmaceuticals, Inc. Announces Initiation Of Phase II/III Study Of Bardoxolone Methyl In The Treatment Of Chronic Kidney Disease Due To Alport Syndrome 2/23/2017
Madrigal Announces The Initiation Of A Phase II Study Of MGL-3196 In Patients With Heterozygous Familial Hypercholesterolemia (HeFH) 2/23/2017
Resverlogix (RVX.TO) Reports Positive FDA Type B Meeting On Design Issues Relating To A Proposed Phase IIa Kidney Dialysis Trial 2/23/2017
Tocagen Achieves Key Development Milestone For Lead Product: Phase II Randomized Trial In Patients With Recurrent Brain Cancer Fully Enrolled 2/23/2017
OncoSec Medical Announces Positive Phase II Data Demonstrating Company's ImmunoPulse IL-12 In Combination With Pembrolizumab Increased Response Rates In Anti-PD-1 Non-Responder Melanoma Patients 2/23/2017
Minoryx Therapeutics Receives Orphan Drug Designation From The FDA For Its Lead Candidate MIN-102 2/22/2017
Soligenix (SNGX) Receives European Patent For Formulation Of Synthetic Hypericin To Treat Psoriasis 2/22/2017
ProMetic Life Sci (PFSCF.PK)'s PBI-4050 Continues To Demonstrate Early Evidence Of Efficacy Following Completion Of Idiopathic Pulmonary Fibrosis Phase II Clinical Trial 2/22/2017
Kalytera Therapeutics Announces Encouraging Results Of A Phase IIa Clinical Study For The Treatment Of Acute Graft Versus Host Disease 2/22/2017
Touchstone Innovations Plc Portfolio Company Cell Medica Granted FDA Fast Track Designation For Lead Oncology Product 2/21/2017
Immuron Completes Phase II NASH Clinical Trial Recruitment 2/21/2017
Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation 2/21/2017
OncoGenex (OGXI) Announces Phase II Apatorsen Data For Two Clinical Trials Presented At The OncoGenex (OGXI) 2017 Genitourinary Cancers Symposium 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
OncoGenex (OGXI) Release: Data Support Continued Exploration Of Hsp27 Inhibition In Bladder And Prostate Cancers 2/21/2017
SoCal's Cidara (CDTX) Stock Sinks as Lead Antifungal Med Flunks Trial 2/21/2017
Lysogene Receives Orphan Drug Designation From EMA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 2/21/2017
3 Biotechs With the Biggest and Most Promising Pipelines 2/20/2017
After Merck & Co. (MRK) & Eli Lilly (LLY) Alzheimer’s Failures, A Look at 7 Companies Still on the Hunt 2/20/2017
Xencor Release: Igg4-Related Disease Biomarker Development Update Presented From An Ongoing, Open-Label, Phase II Study Of Xmab5871 In Igg4-RD At The 3rd International Symposium On Igg4-Related Diseases & Fibrosis 2/20/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase II Study Of Savolitinib In Pulmonary Sarcomatoid Carcinoma 2/20/2017
Phase II Study Supports Potential For Genentech (RHHBY)’s Tecentriq (Atezolizumab) Plus Avastin (Bevacizumab) For People With Locally Advanced Or Metastatic Renal Cell Carcinoma 2/20/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
ASLAN Receives Orphan Drug Designation In Korea For Varlitinib (ASLAN001) In Biliary Tract Cancer 2/20/2017
Bionomics Limited (BNO.AX) Release: New BNC105 Clinical Trial In Combination With Keytruda 2/20/2017
ArmaGen Reports Preliminary Evidence Of Cognitive Improvement In Children With Hurler Syndrome (MPS I) Treated With AGT-181 2/17/2017
Ascendis Announces Publication Of Comprehensive Results From Randomized, Active-Controlled Phase 2 Trial Of Once-Weekly Transcon Growth Hormone In Pediatric Patients 2/17/2017
Viriom Reports Positive Findings In Phase IIb Study Of Elpida As Compared To Efavirenz In Combination With TDF/FTC At CROI 2017 2/17/2017
Kalytera Therapeutics To Announce Phase IIa Clinical Study Results Investigating CBD For The Treatment Of Acute Graft Versus Host Disease 2/17/2017
Adamas Pharma (ADMS) To Present New ADS-5102 Data From Phase II Trial In Walking Impairment Associated With Multiple Sclerosis At ACTRIMS Forum 2017 2/17/2017
Heat Biologics Presents Immune Data On Its HS-410 Phase II Bladder Cancer Trial At The Genitourinary Cancers Symposium 2/17/2017
Capricor Therapeutics, Inc. Terminates Natriuretic Peptide Program Deal With The Mayo Clinic 2/17/2017
Noble Capital Markets Initiates Research Coverage On ESSA Pharma 2/17/2017
Another Drug Bites the Dust: Merck & Co. (MRK) Stops Late-Stage Alzheimer’s Study 2/16/2017
Data Presented At CROI Show CytoDyn (CYDY)’s Pro 140 As A Single Agent Provided Maximal Virologic Suppression In HIV Patients For Nearly Two Years 2/16/2017
ArmaGen CEO: Phase II Data Shows Cognitive Improvement in Juvenile Hurler Syndrome Patients 2/16/2017
AEterna Zentaris (AEZS) Announces Zoptrex Presentation In Prostate Cancer At 2017 Genitourinary Cancers Symposium 2/15/2017
Berg Initiates Phase I/II Monotherapy Trial Of BPM 31510-IV In Patients With Glioblastoma Multiforme (GBM) 2/15/2017
TapImmune (TPIV) Advances TPIV 200 Phase II Triple-Negative Breast Cancer Trial After Favorable DSMB Safety Review 2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Hutchison China MediTech (Chi-Med) And AstraZeneca PLC (AZN) Present Savolitinib Papillary Renal Cell Carcinoma Phase II Results at 2017 Genitourinary Cancers Symposium 2/14/2017
Hutchison China MediTech (Chi-Med): Savolitinib PRCC Results Presentation At ASCO GU 2/14/2017
Aviragen (AVIR) Tanks Some More After Reporting a Second Trial Failure This Month 2/14/2017
Two-Year Update From CytoDyn (CYDY)’s PRO 140 Monotherapy Study In HIV To Be Featured In Two Events At CROI 2017 2/14/2017
Gilead (GILD) Presents New Phase II Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV 2/14/2017
Sanofi (SNY) Initiates Phase II Clinical Trial To Evaluate Therapy For Genetic Form Of Parkinson’s Disease 2/14/2017
Axovant (AXON) Clears an Early Hurdle in Mid-Stage Dementia Trial, But Questions Remain 2/13/2017
SAGE Therapeutics (SAGE) Advances SAGE-217 Into Placebo-Controlled Phase 2 Clinical Trial In Major Depressive Disorder 2/13/2017
DelMar Pharma Announces Dosing Of The First Patient In Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 2/13/2017
Trek Therapeutics Announces Oral Presentation Of Faldaprevir, TD-6450 And Ribavirin Ph2a Trial Results At The Asian Pacific Association For The Study Of The Liver On February 18, 2017 In Shanghai 2/13/2017
Biotron Limited (BIT:AU) Release: Commencement Of BIT225 Phase ll HIV-1 Clinical Trial 2/13/2017
MMJ PhytoTech Phase ll Clinical Trial For Treatment of Epilepsy Underway 2/13/2017
TRACON Pharma (TCON) Announces Top-Line Results From NCI-Sponsored Phase 2 Trial Of TRC105 In Recurrent Glioblastoma 2/10/2017
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017
Neuraltus Pharmaceuticals, Inc. Provides Enrollment Update On Confirmatory Phase II Study Of NP001 In ALS 2/9/2017
Jazz Pharma (JAZZ) Announces First Patient Enrolled In Phase II Clinical Study Evaluating JZP-110 For Excessive Sleepiness In Parkinson's Disease 2/9/2017
ASLAN Reports Positive Top-Line Results For Phase II Clinical Trial Of Varlitinib In Metastatic Breast Cancer 2/9/2017
Iconic Therapeutics, Inc. To Present Phase IIa EMERGE Trial Results At Miami Meeting 2/9/2017
VM BioPharma Announces Publication Of Phase I/II Clinical Data Of Novel Gene Therapy VM202 In Amyotrophic Lateral Sclerosis (ALS) 2/9/2017
CRT Pioneer Fund And Cardiff University Announce The Initiation Of The Phase II MONOCLE Study Of Tefinostat For The Treatment Of Chronic Myelomonocytic Leukaemia With Funding To Progress Further Development 2/8/2017
New FDA Report Cites 22 Drugs That Passed Phase II But Crashed and Burned in Phase III 2/8/2017
MeiraGTx Provides Clinical Trial Updates For Achromatopsia And Leber's Congenital Amaurosis Ocular Gene Therapy Programs 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Aldeyra (ALDX) Announces First Patient Enrolled In Allergic Conjunctivitis Phase IIb Clinical Trial 2/7/2017
Immuron Announces First Patient Enrolled In Pediatric Fatty-Liver Phase II Trial 2/7/2017
GW Pharma (GWPH) Achieves Positive Results In Phase II Proof Of Concept Study In Glioma 2/7/2017
Another Letdown for Bristol-Myers Squibb (BMY) as Partner Innate Pharma (IPH.PA )'s Leukemia Candidate Flunks Phase II Test 2/6/2017
These 5 Biotechs Are Battling Over the $10 Billion Hemophilia Market 2/6/2017
Zealand Pharma  (ZEAL.CO) Release: Patient Recruitment Completed For Phase II Trial With Glepaglutide For Treatment Of Short Bowel Syndrome 2/6/2017
5 Daring Biopharmas Mixing Drugs With Marijuana 2/6/2017
Addex Therapeutics (ADXN.SW)' Clinical Programs And Discovery Platform Highlighted In Review Of Allosteric Modulators For The Treatment Of Neurodegenerative Diseases 2/6/2017
Sirnaomics Initiates A Clinical Phase IIa Study Of Its Leading Sirna Therapeutic Candidate, STP705, For Treatment Of Hypertrophic Scar 2/6/2017
3rd Stemline (STML) Patient Died in Clinical Trial One Day Before $45 Million Public Offering 2/3/2017
Why This Big Biotech Could be Biogen (BIIB)'s Downfall 2/3/2017
Pharmazz Initiates Human Phase II Studies Of PMZ-2010 For The Treatment Of Hemorrhagic Shock And Presents Data At The Society Of Critical Care Medicine Annual Meeting 2/3/2017
Envisia Therapeutics Releases Interim ENV515 (Travoprost XR) Phase II Data Demonstrating 11-Month Duration-Of-Action After A Single Dose In Patients With Glaucoma 2/3/2017



//-->